Moderna, Inc. (MRNA) — AI Signal & News Sentiment
- Price
- $206.23
- Today
- -0.84%
- Signal
- HOLD
- News sentiment, 0–100 (10 articles)
- 30 · Bearish
Moderna, Inc. (MRNA) last traded at $206.23 in after-hours trading, down 0.84% from its last regular close of $207.97. News sentiment is bearish, at 30 on a scale from 0 to 100 where 50 is neutral, based on 10 articles analysed in the last 72 hours. Stock Companion's multi-factor model currently rates MRNA a HOLD with a high risk profile.
Data as of . Signals are generated by an automated model and are not financial advice. How our signals work.
About Moderna, Inc. (MRNA)
Moderna, Inc. (MRNA) is a biotechnology company listed in the United States, carries a market value of about $78.0 billion, has been publicly listed since 2018. Stock Companion scores every headline about it with state-of-the-art AI models trained specifically on financial data. Not investment advice.
Key statistics
| Open | $192.23 |
|---|---|
| Day's range | $179.53 — $208.87 |
| Previous close | $198.85 |
| Market value | $78.0 billion |
| Industry | Biotechnology |
| Listed in | the United States |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Trading currency | USD |
| Public since | 2018 |
Latest scored headlines for MRNA
The 5 most recent of the 10 headlines scored in the last 72 hours, each with its own reading, from state-of-the-art AI models trained specifically on financial data, on the same 0 to 100 scale, where 50 is neutral. The average across all 10 headlines is the sentiment figure above.
- 8Moderna Sinks Another 8% Even as Lead Investigator Calls Melanoma Vaccine Data “Transformational” — Yahoo, 2026-10-26
- 50Moderna’s Rally May Have Run Out of Steam. Here’s What to Watch Next — Yahoo, 2026-10-26
- 50ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data — Yahoo, 2026-10-26
- 12S&P 500 Gap-Down Stocks for Oct. 26, 2026 — ChartMill, 2026-10-26
- 50Moderna’s Cancer Vaccine Rally Hits a Wall. This Other Drugmaker Stole the Show. — Yahoo, 2026-10-26
What is Stock Companion's signal for MRNA?
Stock Companion's multi-factor model currently rates MRNA a HOLD with a high risk profile. That rating combines news sentiment of 30 out of 100 across 10 headlines scored in the last 72 hours with the ticker's price and volatility factors. It is a model output rather than a recommendation, and it moves as the news does. Not investment advice.
What is MRNA's news sentiment today?
30 on a scale from 0 to 100, which we label bearish. It is the average reading that state-of-the-art AI models trained specifically on financial data give the 10 headlines published about Moderna, Inc. (MRNA) in the last 72 hours, recomputed as new headlines arrive. 50 is neutral. We call 48 to 52 neutral; 53 to 59 slightly bullish, 60 to 74 bullish and 75 or more very bullish; 41 to 47 slightly bearish, 26 to 40 bearish and 25 or less very bearish. Not investment advice.
How does Stock Companion score MRNA's news?
Every headline is scored by state-of-the-art AI models trained specifically on financial data, and those scores are averaged into the one number shown above, on a scale from 0 to 100 where 50 is neutral. That number is the same for every visitor, on every page, whatever their plan. The signal then adds price and volatility factors to it. The full method is on our methodology page. Not investment advice.
Sources and method: every headline above is scored by state-of-the-art AI models trained specifically on financial data and the aggregate is the same for every visitor. How our signals work.